SR-3306 is a brain-penetrant and selective pan-JNK (JNK1/2/3) inhibitor with IC50 values ​​of 67 nM, 283 nM, 159 nM, respectively, and reduces food intake and body weight.

METHODS: SR-3306 (0.001-100 μM) was used to treat cisplatin-resistant ovarian cancer cells to study its anticancer activity.
RESULTS SR-3306 had inhibitory activity against cisplatin-resistant ovarian cancer cells, with an IC50 value of 0.05 μM. [4]

METHODS: Dopaminergic neurons were labeled with antibodies against tyrosine hydroxylase (TH) in brain sections from rats treated with 6-OHDA. Rats received SR-3306 (2.5 mg/kg, 10 mg/kg, subcutaneously, for 14 days). The ability of SR-3306 to prevent nigrostriatal neuronal loss was examined in the 6-OHDA model.
RESULTS 6-OHDA-lesioned rats treated with 2.5 mg/kg SR-3306 showed a slight increase in ipsilateral TH-positive neurons, and 10 mg/kg SR-3306 had a significant protective effect against 6-OHDA-induced neurodegeneration when the contralateral side was compared with the ipsilateral side. [1]
METHODS: Wild-type lean mice were given SR3306 (30, 60 mg/kg, intraperitoneal injection) to study the effects of SR3306 on food intake and energy balance.
RESULTS 30 mg/kg of SR3306 did not affect saccharin intake preference, while a dose of 60 mg/kg produced a strong avoidance response to saccharin. [2]